Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes,
macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells
(HSPC) in the bone marrow. 68Ga-Pentixafor PET/CT represents a promising method for the in
vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic
malignancies. This prospective study is going to investigate whether metabolic
characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk
stratification, and the prognostic evaluation in lymphoproliferative diseases.
Phase:
Early Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University